A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMvigor 010
- Sponsors Chugai Pharmaceutical; Roche
- 10 Jul 2017 Planned primary completion date changed from 30 Jun 2017 to 4 Oct 2019.
- 10 Jun 2017 Biomarkers information updated
- 17 Mar 2017 Planned primary completion date changed from 1 Jun 2022 to 30 Jun 2017.